Novo pioneered GLP-1 therapy: it launched Victoza (liraglutide) for diabetes in 2010 and then Wegovy (semaglutide 2.4 mg injection) for obesity in 2021 ( [14] ) ( [18] )
L.WintermantelW
A recent randomized study comparing structured lifestyle modification (a cornerstone in the currently recommended treatment of NASH) to liraglutide 3 mg/day without lifestyle modifications showed similar reductions in ALT and liver stiffness with no difference in bodyweight variations
In clinical trials, patients using injectable semaglutide lost an average of 15% to 16% of their body weight over 64 weeks, while those using an oral semaglutide formulation lost approximately 13%. The difference is meaningful but modest, and for many people the convenience and lower friction of an oral format may more than offset a slightly lower average weight loss
Avances recientes en el Tratamiento Farmacolgico de la obesidad En la ltima dcada, hemos presenciado una revolucin en la farmacologa de la obesidad, con el desarrollo de frmacos que abordan los mecanismos subyacentes del apetito y la saciedad
This synergistic interaction enhances resilience against oxidative stress and supports continuous redox cycling in experimental models of aging and cellular defense